BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pryseley A, Tilahun A, Alonso A, Molenberghs G. An information-theoretic approach to surrogate-marker evaluation with failure time endpoints. Lifetime Data Anal 2011;17:195-214. [DOI: 10.1007/s10985-010-9185-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Honerkamp-Smith G, Xu R. Three measures of explained variation for correlated survival data under the proportional hazards mixed-effects model. Stat Med 2016;35:4153-65. [PMID: 27241815 DOI: 10.1002/sim.6993] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Dimier N, Todd S. Assessment of the information theory approach to evaluating time-to-event surrogate and true endpoints in a meta-analytic setting. Pharm Stat 2021;20:335-47. [PMID: 33145928 DOI: 10.1002/pst.2080] [Reference Citation Analysis]
3 Andrew Moore R. Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage. Arthritis Res Ther 2013;15 Suppl 3:S4. [PMID: 24267380 DOI: 10.1186/ar4176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
4 Ensor H, Weir CJ. Evaluation of surrogacy in the multi-trial setting based on information theory: an extension to ordinal outcomes. J Biopharm Stat 2020;30:364-76. [PMID: 31887069 DOI: 10.1080/10543406.2019.1696357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ensor H, Weir CJ. Separation and the information theory surrogate evaluation approach: A penalised likelihood solution. Pharm Stat 2021. [PMID: 34328255 DOI: 10.1002/pst.2152] [Reference Citation Analysis]
6 Ensor H, Lee RJ, Sudlow C, Weir CJ. Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review. Journal of Biopharmaceutical Statistics 2016;26:859-79. [DOI: 10.1080/10543406.2015.1094811] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
7 Rava D, Xu R. Explained variation under the additive hazards model. Stat Med 2021;40:85-100. [PMID: 33000531 DOI: 10.1002/sim.8763] [Reference Citation Analysis]
8 Dimier N, Todd S. An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest. Pharm Stat 2017;16:322-33. [PMID: 28544622 DOI: 10.1002/pst.1812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
9 Chan PH, Xu R, Chambers CD. A Study of R2 Measure under the Accelerated Failure Time Models. Commun Stat Simul Comput 2018;47:380-91. [PMID: 29628607 DOI: 10.1080/03610918.2016.1177072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]